Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemigliptin - LG Chem

Drug Profile

Gemigliptin - LG Chem

Alternative Names: Gemigliptin tartrate sesquihydrate; Gemiglo®; LC-150444; Zemiglo

Latest Information Update: 02 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem; Sanofi
  • Class Antihyperglycaemics; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II/III Acute kidney injury

Most Recent Events

  • 24 Jun 2023 Efficacy and adverse event data from a phase III trial in Type 2 diabetes mellitus presented at the83rd Annual Scientific Sessions of the American Diabetes Association (ADA-2023)
  • 30 Nov 2022 LG Chem completes the phase III SOLUTION clinical trial for Type II diabetes mellitus in South Korea (PO) (NCT03842267)
  • 28 Aug 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in China (PO, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top